Sponsored by:

Molecular Imaging: Page 494

Limiting scan range cuts dose, boosts throughput in melanoma PET/CT
By Jonathan S. Batchelor
ORLANDO, FL - The current PET/CT protocol of scanning all melanoma patients from the crown of the head to the soles of the feet, including dedicated brain studies, may be providing little clinical value and putting patients on the gantry longer than needed, according to a study from the David Geffen School of Medicine at the University of California, Los Angeles (UCLA).
March 29, 2006
PET/CT shows virtual bronchoscopy potential
By Jonathan S. Batchelor
ORLANDO, FL - Three-dimensional visualization with PET/CT may soon be expanded to virtual bronchoscopy, providing a new tool for diagnosis, treatment planning, and interventional guidance, according to a multidisciplinary group from Stanford University in California.
March 29, 2006
MRI, PET disclose neurological decline in preclinical Huntington's disease
By Shalmali Pal
Years before Huntington's becomes a full-blown disease, a genetic mutation may be found in some people that predisposes them to the degenerative illness. Earlier brain imaging studies have shown that progressive neuronal dysfunction may influence the clinical course of the disease. Now researchers from Italy and the U.K. have applied MRI and FDG-PET to the presymptomatic brain in Huntington's disease.
March 29, 2006
2006 03 29 15 57 47 706
Rising serum markers trigger first-line PET investigation
By Jonathan S. Batchelor
ORLANDO, FL - The post-therapy cancer protocol at many institutions is to watch and wait. If patients manifest elevated serum tumor markers such as S100 or carcinoembryonic antigen (CEA) during this follow-up period, conventional diagnostic methods call for the use of anatomic imaging first, then molecular imaging if necessary. A group in the Netherlands has flipped the imaging order, using PET as the primary imaging modality for occult tumors.
March 28, 2006
DraxImage shelves Fibrimage, unveils new generics initiative
By AuntMinnie.com staff writers
Radiopharmaceutical firm DraxImage has decided to realign its research and development activities, a process that will include a new effort to develop generic radiopharmaceuticals.
March 27, 2006
VisEn debuts optical imaging probes
By AuntMinnie.com staff writers
Optical imaging developer VisEn Medical is introducing its NanoSparks line of optical imaging probes at this week’s annual conference of the Academy of Molecular Imaging (AMI) in Orlando, FL.
March 27, 2006
Molecular Insight begins phase II clinical trial
By AuntMinnie.com staff writers
Molecular Insight Pharmaceuticals has begun a phase II clinical trial of its Zemiva molecular imaging pharmaceutical.
March 26, 2006
PET registry primed for takeoff
By Jonathan S. Batchelor
ORLANDO, FL - The National Oncologic PET Registry (NOPR), which debuted last year at the Academy of Molecular Imaging (AMI) annual meeting, holds the promise of broadening the scope of the types of oncologic PET scans that can be conducted on Medicare patients. Dr. Barry Siegel from the Mallinckrodt Institute of Radiology in St. Louis presented an update on the status of the project at the 2006 AMI meeting on Sunday.
March 26, 2006
Siemens to unveil Inveon, 40-slice PET/CT, at AMI
By AuntMinnie.com staff writers
Siemens Medical Solutions is introducing a new preclinical imaging product, Inveon, at next week's Academy of Molecular Imaging (AMI) meeting in Orlando, FL.
March 23, 2006
PET shows staging strength in esophageal cancer
By AuntMinnie.com staff writers
PET is more accurate than conventional imaging in identifying esophageal cancer patients who have good responses to chemotherapy and radiation treatment, according to a report in next month's Annals of Surgery.
March 22, 2006
ART begins Princess Margaret trial
By AuntMinnie.com staff writers
Canadian optical molecular imaging developer ART Advanced Research Technologies has begun clinical trials of its SoftScan optical breast imaging system at Princess Margaret Hospital in Toronto.
March 21, 2006
Positron gets Health Canada nod
By AuntMinnie.com staff writers
PET vendor Positron said that Health Canada had granted approval to use the vendor's mPower PET scanner in oncology and cardiology clinical trials in Canada.
March 21, 2006
Previous Page
Page 494 of 615
Next Page